JP7167021B2 - アルブミン結合ｐｓｍａ阻害剤 - Google Patents

アルブミン結合ｐｓｍａ阻害剤 Download PDF

Info

Publication number
JP7167021B2
JP7167021B2 JP2019527426A JP2019527426A JP7167021B2 JP 7167021 B2 JP7167021 B2 JP 7167021B2 JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019527426 A JP2019527426 A JP 2019527426A JP 7167021 B2 JP7167021 B2 JP 7167021B2
Authority
JP
Japan
Prior art keywords
compound
formula
independently
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019527426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535754A (ja
JP2019535754A5 (enExample
Inventor
クリフォード バークマン，
シンディー チョイ，
Original Assignee
キャンサー ターゲテッド テクノロジー エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャンサー ターゲテッド テクノロジー エルエルシー filed Critical キャンサー ターゲテッド テクノロジー エルエルシー
Publication of JP2019535754A publication Critical patent/JP2019535754A/ja
Publication of JP2019535754A5 publication Critical patent/JP2019535754A5/ja
Application granted granted Critical
Publication of JP7167021B2 publication Critical patent/JP7167021B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019527426A 2016-11-23 2017-11-24 アルブミン結合ｐｓｍａ阻害剤 Expired - Fee Related JP7167021B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
US62/425,810 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (3)

Publication Number Publication Date
JP2019535754A JP2019535754A (ja) 2019-12-12
JP2019535754A5 JP2019535754A5 (enExample) 2021-01-07
JP7167021B2 true JP7167021B2 (ja) 2022-11-08

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527426A Expired - Fee Related JP7167021B2 (ja) 2016-11-23 2017-11-24 アルブミン結合ｐｓｍａ阻害剤

Country Status (8)

Country Link
US (1) US11147889B2 (enExample)
EP (1) EP3544960A1 (enExample)
JP (1) JP7167021B2 (enExample)
CN (1) CN109982998A (enExample)
BR (1) BR112019010206A2 (enExample)
CA (1) CA3043619A1 (enExample)
MX (1) MX2019005742A (enExample)
WO (1) WO2018098390A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018352731B2 (en) * 2017-10-22 2023-10-05 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
WO2019246445A1 (en) * 2018-06-20 2019-12-26 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
EP3880253A1 (en) 2018-11-14 2021-09-22 Noria Therapeutics, Inc. Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
CA3136979A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
WO2020252598A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
TWI908773B (zh) 2020-03-04 2025-12-21 日商日本醫事物理股份有限公司 化合物及放射性標誌化合物
JP7894086B2 (ja) * 2020-05-06 2026-07-23 コーネル ユニヴァーシティー 銅含有セラグノスティック化合物及びその使用の方法
CN116829541A (zh) * 2020-12-04 2023-09-29 加利福尼亚大学董事会 肽受体放射性核素治疗
US20240018110A1 (en) * 2020-12-16 2024-01-18 The University Of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
US20240174622A1 (en) 2021-03-04 2024-05-30 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
CA3244865A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
EP4667019A1 (en) * 2023-02-16 2025-12-24 Norroy Bioscience Co., Ltd. Psma-targeted radiopharmaceutical, and synthesis and use thereof
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108125A2 (en) 2009-03-19 2010-09-23 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
JP2014524419A (ja) 2011-08-05 2014-09-22 モレキュラー インサイト ファーマシューティカルズ 放射標識された前立腺特異的膜抗原阻害剤
WO2016030329A1 (en) 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
JP2018531243A (ja) 2015-09-30 2018-10-25 ドイチェス クレブスフォルシュンクスツェントルム 前立腺特異的膜抗原（ｐｓｍａ）の１８ｆ−タグ付加インヒビターおよび前立腺癌についての画像化剤としてのその使用
JP2019535727A (ja) 2016-11-18 2019-12-12 エービーエックス・アドヴァンスド・バイオケミカル・コンパウンズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ラジオフッ素化のための前駆体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
CN106061981A (zh) * 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体
WO2015073678A1 (en) * 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
KR20250057132A (ko) * 2016-03-22 2025-04-28 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
SG11201811482YA (en) * 2016-06-23 2019-01-30 Univ Cornell Double targeted constructs to affect tumor kill

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108125A2 (en) 2009-03-19 2010-09-23 The Johns Hopkins University Psma-targeting compounds and uses thereof
JP2014524419A (ja) 2011-08-05 2014-09-22 モレキュラー インサイト ファーマシューティカルズ 放射標識された前立腺特異的膜抗原阻害剤
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
WO2016030329A1 (en) 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
JP2018531243A (ja) 2015-09-30 2018-10-25 ドイチェス クレブスフォルシュンクスツェントルム 前立腺特異的膜抗原（ｐｓｍａ）の１８ｆ−タグ付加インヒビターおよび前立腺癌についての画像化剤としてのその使用
JP2019535727A (ja) 2016-11-18 2019-12-12 エービーエックス・アドヴァンスド・バイオケミカル・コンパウンズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ラジオフッ素化のための前駆体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Liolios, C. et al.，Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer，Bioconjugate Chemistry，2016年，27(3)，737-751
REGISTRY（STN)[online]，2013.03.03[検索日 2021.10.16]CAS登録番号 1422239-57-3
Shallal, Hassan M. et al.，Heterobivalent Agents Targeting PSMA and Integrin-αvβ3，Bioconjugate Chemistry ，2014年，25(2)，393-405

Also Published As

Publication number Publication date
BR112019010206A2 (pt) 2019-09-03
US11147889B2 (en) 2021-10-19
EP3544960A1 (en) 2019-10-02
JP2019535754A (ja) 2019-12-12
WO2018098390A1 (en) 2018-05-31
MX2019005742A (es) 2019-09-13
CN109982998A (zh) 2019-07-05
CA3043619A1 (en) 2018-05-31
US20200061218A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CN109982998A (zh) 白蛋白结合psma抑制剂
Usama et al. Role of albumin in accumulation and persistence of tumor-seeking cyanine dyes
CN103930432B (zh) 螯合的psma抑制剂
Yim et al. Synthesis of DOTA-conjugated multimeric [Tyr3] octreotide peptides via a combination of Cu (I)-catalyzed “click” cycloaddition and thio acid/sulfonyl azide “sulfo-click” amidation and their in vivo evaluation
CN103874512B (zh) 选择性递送分子及使用方法
JP2022176252A (ja) キレート化されたｐｓｍａ阻害剤
Qian et al. pH-triggered peptide self-assembly for targeting imaging and therapy toward angiogenesis with enhanced signals
CA2732632C (en) Psma-binding agents and uses thereof
JP6968921B2 (ja) 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
JP7646637B2 (ja) 画像化及び治療用組成物
CN116217505B (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
JP2023554079A (ja) リガンド及びそれらの使用
JP2014501714A5 (enExample)
KR20260072597A (ko) 양쪽성 금속 킬레이트제
Kwon et al. Synthesis and evaluation of multifunctional fluorescent inhibitors with synergistic interaction of prostate-specific membrane antigen and hypoxia for prostate cancer
US12268742B2 (en) Nanotherapeutic systems and methods using particle-driven photodynamic therapy (PDT)
US20150217006A1 (en) Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
US9956303B2 (en) Anti-met therapy for previously diagnosed cancer patients
NL2027653B1 (en) Targeting system with improved uptake
Su et al. Site-specific albumin tagging with chloride-containing near-infrared cyanine dyes: molecular engineering, mechanism, and imaging applications
EP4705295A2 (en) Multifunctional compound core for active agents and uses thereof
CN118324852A (zh) 一种靶向pd-l1的多肽及其应用
US11795197B2 (en) Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
US20250082795A1 (en) Combinations of imaging agent conjugates and application thereof
WO2024264053A2 (en) Trans-cyclooctene compounds and methods of use in the synthesis of pet probes and radioisotope based therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221026

R150 Certificate of patent or registration of utility model

Ref document number: 7167021

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees